Medpace Holdings (MEDP) Aktienübersicht
Medpace Holdings, Inc. bietet auf klinischer Forschung basierende Dienstleistungen zur Entwicklung von Medikamenten und medizinischen Geräten in Nordamerika, Europa, Asien, Südamerika, Afrika und Australien an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 4/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
MEDP Community Fair Values
Create NarrativeSee what 80 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medpace Holdings, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$590.67 |
| 52-Wochen-Hoch | US$677.90 |
| 52-Wochen-Tief | US$373.00 |
| Beta | 1.15 |
| 1 Monat Veränderung | 9.74% |
| 3 Monate Veränderung | 41.55% |
| 1 Jahr Veränderung | 35.99% |
| 3 Jahre Veränderung | 121.32% |
| 5 Jahre Veränderung | 232.42% |
| Veränderung seit IPO | 2,006.53% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 27
MEDP: Bookings Inflection And Metabolic Mix Shifts Will Strain Rich P E Multiple
For this Narrative Update on Medpace Holdings, the analyst-derived fair value estimate has been lifted from about $349.93 to $399.43, as analysts point to stronger bookings visibility, a healthier non-metabolic mix, and updated models following Q2 results that support a modestly higher future P/E assumption despite slightly lower margin expectations. Analyst Commentary Recent Street research on Medpace Holdings reflects a mix of enthusiasm around bookings trends and more guarded views on how valuation, revenue mix, and growth expectations line up after the latest Q2 update.Seeking Alpha • Jul 25
Medpace: Cancellations Are Normalizing
Summary Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027. Valuation remains historically expensive (P/E ~35, P/FCF >24), making the current buying case weaker despite improved business momentum. Read the full article on Seeking AlphaRecent updates
Narrative-Update • Jul 27
MEDP: Bookings Inflection And Metabolic Mix Shifts Will Strain Rich P E Multiple
For this Narrative Update on Medpace Holdings, the analyst-derived fair value estimate has been lifted from about $349.93 to $399.43, as analysts point to stronger bookings visibility, a healthier non-metabolic mix, and updated models following Q2 results that support a modestly higher future P/E assumption despite slightly lower margin expectations. Analyst Commentary Recent Street research on Medpace Holdings reflects a mix of enthusiasm around bookings trends and more guarded views on how valuation, revenue mix, and growth expectations line up after the latest Q2 update.Seeking Alpha • Jul 25
Medpace: Cancellations Are Normalizing
Summary Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027. Valuation remains historically expensive (P/E ~35, P/FCF >24), making the current buying case weaker despite improved business momentum. Read the full article on Seeking Alpha
Narrative-Update • Jul 13
MEDP: Rich Valuation And Volatile Earnings Reactions Will Constrain Future Upside
The analyst price target for Medpace Holdings has been raised from $443.50 to $456.00 as analysts factor in steady healthcare utilization trends, modest adjustments to discount rates and growth assumptions, and mixed but generally higher Street targets that balance optimism around demand with greater caution on valuation and near term volatility. Analyst Commentary Recent research on Medpace Holdings points to a split view, with bullish analysts focusing on solid end market indicators and higher price targets, while more cautious voices highlight valuation sensitivity and near term trading swings around earnings events.Narrative-Update • Jun 29
MEDP: Slower Revenue Outlook And Lower P/E Assumptions Will Pressure Expectations
Analysts have trimmed their price targets on Medpace Holdings, with the updated fair value estimate moving from $500.08 to $443.50 as they factor in slightly higher discount rates, more moderate revenue growth assumptions, a marginally lower profit margin outlook, and a modestly reduced future P/E multiple. Analyst Commentary Recent research updates on Medpace Holdings point to a more cautious stance on valuation, with several firms trimming their price targets even as they recognize the company’s execution strengths and long-term opportunities.Analyseartikel • Jun 16
Medpace Holdings (MEDP) Stock Valuation Check After Mixed Recent Share Performance
Medpace Holdings overview after recent share performance Medpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to review how its current valuation lines up with recent fundamentals. See our latest analysis for Medpace Holdings. That recent 12.6% 1 month share price return stands out against a weaker year to date share price return, while a 1 year total shareholder return of 56.9% suggests longer term holders have still...
Narrative-Update • Jun 15
MEDP: AI Demand And Governance Reforms Will Offset Legal And Forecast Reset Risks
Analysts trimmed their Medpace Holdings price targets by $38 to $88, citing updated assumptions for revenue growth, profit margins, discount rates, and future P/E. Together, these factors support a more measured view of upside from current levels.Narrative-Update • Jun 01
MEDP: Legal And Backlog Disclosure Risks Will Challenge Rich Future P E Multiple
Analysts have trimmed their average price target on Medpace Holdings by aligning with recent cuts from several brokers. This reflects updated views on discount rates, revenue growth assumptions, profit margins and future P/E expectations, and now anchors fair value around $349.93 per share.Narrative-Update • May 14
MEDP: Slower Long Term Revenue Assumptions Will Challenge Rich P E Multiple
Medpace Holdings' fair value estimate has been trimmed by about $7 to $349.93 as analysts moderate long term revenue growth assumptions, while still recognizing higher profit margins and a slightly higher forward P/E in their updated price targets. Analyst Commentary Recent Street research on Medpace highlights a mix of cautious and constructive views, with several firms revising price targets and ratings as they reassess growth assumptions, margins, and sector trends in clinical research outsourcing.Narrative-Update • Apr 29
MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Resilience
Medpace Holdings' analyst price target has been reset from about $582 to roughly $495 as analysts factor in updated assumptions for revenue growth, margins and future P/E multiples, while still pointing to company specific strengths highlighted in recent research coverage and upgrades. Analyst Commentary Street research around Medpace has recently centered on recalibrating price targets while still emphasizing company specific strengths.Analyseartikel • Apr 26
Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 21% to US$411 in the week...Narrative-Update • Apr 15
MEDP: Slower Revenue Assumptions Will Test Rich Multiple And 2026 Execution
Medpace Holdings' analyst-derived fair value has inched up by about $5 to roughly $357, as analysts weigh higher assumed profit margins and a richer future P/E against slower projected revenue growth and a slightly higher discount rate, while incorporating a wave of recent rating upgrades and higher price targets clustered around $419 to $522. Analyst Commentary Recent research on Medpace reflects a mix of upgrades and cautious fine tuning, with several firms lifting ratings while keeping a close eye on valuation, end market trends, and execution risk.Narrative-Update • Apr 01
MEDP: Efficient Biotech Contracts And Buybacks Will Support Elevated Market Expectations
Analysts have inched up their blended price target on Medpace Holdings to about $500 per share from roughly $490, citing the company’s efficiency in contract research, ongoing biotech-focused wins, and a series of recent rating upgrades as key reasons for this recalibration. Analyst Commentary Recent research remains broadly constructive on Medpace, with several firms adjusting ratings and price targets as they reassess valuation, execution, and exposure to biotech customers.Narrative-Update • Mar 18
MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Strength
Analysts have nudged their overall price expectations for Medpace modestly higher, reflected in a slightly lower discount rate of 7.78% and small upward tweaks to revenue growth and profit margin assumptions. These changes are supported by a series of recent rating upgrades and fresh price targets in the $419 to $660 range.Narrative-Update • Mar 03
MEDP: Efficiency And Biotech Exposure Will Support Margin Strength Going Forward
Analysts have lifted their implied fair value estimate for Medpace Holdings to $582 from $510, citing the company's efficiency as a contract research organization, stronger profit margin assumptions at 17.94%, and a higher future P/E of about 29.35x as key supports for the updated price targets across recent research. Analyst Commentary Recent research coverage has highlighted a generally constructive tone around Medpace, with several bullish analysts pointing to efficiency, exposure to biopharma clients, and margin profile as key parts of the equity story.Narrative-Update • Feb 17
MEDP: Higher Margins And Buybacks Will Support Rich Market Expectations
Analysts have trimmed their average price target on Medpace Holdings by about $55 to $490.50 as revised models reflect updated revenue growth assumptions, a slightly different discount rate, higher expected profit margins, and a higher future P/E multiple, informed by a mix of recent upgrades and target changes across the Street. Analyst Commentary Recent research has produced a mix of upgrades and target cuts, with Street views clustering around how sustainable Medpace Holdings' growth, margins, and valuation may be after the latest earnings move.Analyseartikel • Feb 13
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 23% to US$416 in the week...Narrative-Update • Feb 03
MEDP: Decelerating Healthcare Utilization Will Test Rich Multiple And 2026 Execution
Analysts have nudged their price target for Medpace Holdings slightly higher, to $660 from $655, citing updated Q4 healthcare utilization survey findings and modest tweaks to growth, margin and future P/E assumptions in their models. Analyst Commentary Recent research around Medpace focuses on how healthcare utilization trends could influence growth expectations, margins and the valuation investors are willing to pay.Narrative-Update • Jan 20
MEDP: Biotech Recovery And Backlog Strength Will Challenge Rich Market Expectations
Narrative Update: Medpace Holdings Analyst Price Target Shift The updated analyst framework edges fair value for Medpace Holdings slightly higher to about $545.75 from roughly $541.92. This reflects modest tweaks to discount rate, growth, margin and P/E assumptions as analysts respond to a series of recent price target increases across the Street.Narrative-Update • Jan 06
MEDP: Rich Multiple Will Depend On Unproven 2026 Execution
Analysts raised their fair value estimate for Medpace Holdings from about $305 to roughly $356 per share, citing higher assumed revenue growth, slightly improved profit margins, and a modestly higher future P/E multiple in line with recent Street price target increases. Analyst Commentary Recent Street research on Medpace highlights a mix of optimism on the long term setup and caution around how much upside is already reflected in the current share price.Narrative-Update • Dec 21
MEDP: Biotech Funding Recovery And Backlog Trends Will Shape Future Prospects
Analysts have nudged their blended fair value estimate for Medpace Holdings slightly higher, to approximately $542 from $539, citing increased confidence in the durability of biotech recovery, a healthier pre-backlog pipeline, and signs that contract research trends have stabilized. Analyst Commentary Street research updates over the last several weeks reflect a generally constructive stance on Medpace, with multiple firms raising price targets while maintaining a range of ratings from Sell to Outperform.Narrative-Update • Dec 07
MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook
Analysts have nudged their price target on Medpace Holdings modestly higher by about $2 per share to reflect increased confidence in a sustained recovery in biotech funding, healthier book to bill trends, and signs that contract research organization demand has likely stabilized. Analyst Commentary Recent Street research reflects a more constructive stance on Medpace, with several bullish analysts lifting price targets to account for stronger sector fundamentals and improved visibility into the company’s growth trajectory.Narrative-Update • Nov 22
MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum
The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.Narrative-Update • Nov 07
MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion
Analysts have raised their price target for Medpace Holdings from $456 to approximately $519, citing higher growth estimates and renewed confidence in the CRO sector's recovery. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for Medpace, citing increased confidence in the recovery trajectory of the biotech sector and the broader contract research organization market.Narrative-Update • Oct 24
Future Sector Demand Shifts Will Influence Risk And Reward Dynamics
Analysts have raised their fair value estimate for Medpace Holdings to $456 from $428 per share. This change reflects updated optimism based on recent price target adjustments and expectations for stabilization in contract research organization demand trends.Narrative-Update • Oct 09
Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.Narrative-Update • Sep 04
Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).Analyseartikel • Aug 11
Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%
Medpace Holdings, Inc. ( NASDAQ:MEDP ) shareholders have had their patience rewarded with a 34% share price jump in the...Seeking Alpha • Feb 06
Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Summary Medpace has had an excellent financial performance. Its revenues increased by 495.26% between 2016Q2 and 2024Q3. Meanwhile, its current ROE is 54.08%. The company focused on small and mid-size companies. In this segment, the company has gained competitive advantages. Despite the fact that Medpace has received high backlog cancellations, the company is still a solid firm, and it grew by 9.81% between 2023 and 2024Q3 TTM. In the short term, the CRO market will face a difficult time, but the market outlook for the long term expects an improvement. Read the full article on Seeking AlphaSeeking Alpha • Oct 26
Medpace: Buy The Short-Term Pain For Long-Term Gains
Summary Medpace Holdings' stock fell after Q3 earnings due to revenue growth concerns and a low book-to-bill ratio, but the long-term prospects remain strong. Medpace offers full-service clinical trial management, catering mainly to small biopharma companies lacking trial expertise, making it a stand-out player in the CRO market. Despite short-term revenue growth issues, Medpace's financials are impressive, with high profitability, no debt, and strong returns on capital, justifying a Buy rating. The stock is reasonably priced, trading below historical averages, and is poised for long-term growth, especially if biopharma funding rebounds as expected. Read the full article on Seeking AlphaSeeking Alpha • Oct 16
Why Medpace Holdings Is A 'Better Mousetrap'
Summary Initiated a position in Medpace, increased investment after Q2 earnings miss; believe stock issues are temporary, presenting a buying opportunity. Medpace, a niche leader in CRO industry, operates under a full-service outsourcing model, serving small biotech companies with high-value, tailored solutions. Impressive financials: 20%+ revenue growth, 100%+ free cash flow conversion, 50%+ return on invested capital, large growth runway in a growing market. Stock price down 20% due to biotech R&D slowdown; long-term industry drivers intact, Medpace trading at an attractive valuation with superior growth prospects. Read the full article on Seeking AlphaAktionärsrenditen
| MEDP | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 2.3% | 3.6% | 2.7% |
| 1Y | 36.0% | 25.6% | 20.9% |
Rendite im Vergleich zur Industrie: MEDP übertraf die Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 25.6 erzielte.
Rendite vs. Markt: MEDP übertraf den Markt US, der im vergangenen Jahr eine Rendite von 20.9 erzielte.
Preisvolatilität
| MEDP volatility | |
|---|---|
| MEDP Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: MEDP hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: MEDPDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1992 | 6,500 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. bietet auf klinischer Forschung basierende Dienstleistungen für die Entwicklung von Medikamenten und Medizinprodukten in Nordamerika, Europa, Asien, Südamerika, Afrika und Australien an. Das Unternehmen bietet eine Reihe von Dienstleistungen an, die den klinischen Entwicklungsprozess von Phase I bis Phase IV in verschiedenen therapeutischen Bereichen unterstützen. Es bietet klinische Entwicklungsdienstleistungen für die Pharma-, Biotechnologie- und Medizinprodukteindustrie sowie Entwicklungsplangestaltung, koordiniertes Zentrallabor, Projektmanagement, regulatorische Angelegenheiten, klinische Überwachung, Datenmanagement und -analyse, Einreichung von Anträgen für neue Arzneimittel im Rahmen der Pharmakovigilanz und klinische Unterstützungsdienste nach der Markteinführung.
Medpace Holdings, Inc.'s Grundlagenzusammenfassung
| MEDP grundlegende Statistiken | |
|---|---|
| Marktanteil | US$16.49b |
| Gewinn(TTM) | US$491.50m |
| Umsatz(TTM) | US$2.78b |
33.5x
Kurs-Gewinn-Verhältnis 5.9x
Kurs-Umsatz-VerhältnisIst MEDP zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MEDP Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$2.78b |
| Kosten der Einnahmen | US$769.32m |
| Bruttogewinn | US$2.01b |
| Sonstige Ausgaben | US$1.52b |
| Gewinn | US$491.50m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 17.61 |
| Bruttomarge | 72.35% |
| Nettogewinnspanne | 17.67% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich MEDP auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/09 04:31 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Medpace Holdings, Inc. wird von 21 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |